Radioactive Label Patents (Class 436/504)
  • Patent number: 9395376
    Abstract: The present invention encompasses a method for screening for a kokumi-imparting substance by using the calcium receptor activity as an index, a composition containing a kokumi-imparting substance obtained by the screening method, a method for producing food or drink imparted with kokumi, and food or drink imparted with kokumi.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: July 19, 2016
    Assignee: AJINOMOTO CO., INC.
    Inventors: Takeaki Ohsu, Sen Takeshita, Yuzuru Eto, Yusuke Amino, Naohiro Miyamura, Tomohiko Yamanaka, Hiroaki Nagasaki
  • Patent number: 8956811
    Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: February 17, 2015
    Assignee: Genentech Inc.
    Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
  • Patent number: 8956878
    Abstract: The present application is directed to a peptides comprising an a-helix forming-amino acid sequence that binds a heat shock protein. Also included is a polypeptide comprising (a) a first peptide portion that comprises an ?-helix-forming amino acid sequence that binds a heat shock protein; and (b) at least one second peptide portion comprising an antigenic amino acid sequence and/or an a-helix-stabilizing amino acid sequence that increases the interaction of the first peptide portion with the heat shock protein. The present application also includes compositions comprising the peptides and/or polypeptides of present application and uses of the peptides and/or polypeptides of the present application for fractionating substances relevant for discovery, research or clinical analysis from a biological sample and as therapeutics.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: February 17, 2015
    Assignees: Atlantic Cancer Research Institute, New England Peptide, Inc.
    Inventors: Steven Gareth Griffiths, Scott Edwin Lewis
  • Patent number: 8685666
    Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: April 1, 2014
    Assignee: The Board of Trustees of Southern Illinois University
    Inventor: Deliang Cao
  • Patent number: 8614065
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: December 24, 2013
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Ekkehard Mössner
  • Patent number: 8486657
    Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: July 16, 2013
    Inventors: Xiaohong Cai, Thomas Cai
  • Patent number: 8470548
    Abstract: The present invention relates to the use of p11 as a drug target as well as a tool for the diagnosis, treatment and development of p11/5-HT receptor related disorders. The invention further relates to p11 knock-out animals as well as p11 transgenic animals and their use as models for the development of novel psychotherapeutic agents, and to methods of diagnosis, prophylaxis and treatment of p11/5-HT receptor related disorders.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: June 25, 2013
    Assignee: Intra-Cellular Therapies, Inc.
    Inventors: Per Svenningsson, Paul Greengard
  • Patent number: 8404459
    Abstract: The invention pertains to a method of measuring A? protofibrils in a sample. The method includes the steps of (a) providing a labeled monoclonal antibody or fragment thereof that binds wildtype A? 42/40 protofibril and A?42/40 Arc protofibril and has no or little cross-reactivity to A? 42/40 monomers with an agent that generates a measurable signal, (b) contacting said labeled antibody or fragment thereof with the fluid or tissue having or suspected of comprising A? protofibrils, and (c) measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: March 26, 2013
    Assignee: BioArctic Neuroscience AB
    Inventors: Pär Gellerfors, Lars Lannfelt
  • Patent number: 8394646
    Abstract: A method for quality control of species used in analytical or diagnostic or therapeutic procedures includes immobilization of a model of the malignancy to a solid support (121), contacting the solid support with species dissolved in liquid (122), measuring both the rate of formation of complex and absolute magnitude of number of complexes of model and species (123) and determining the quality of species by comparing the measured values with predetermined values.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: March 12, 2013
    Assignee: Ridgeview Instruments AB
    Inventor: Magnus Malmqvist
  • Patent number: 8383360
    Abstract: The present invention provides diagnostic methods for determining the risk of developing an autism spectrum disorder (ASD) in a fetus or child by detecting in a biological sample from the mother antibodies that bind to one or more biomarkers selected from the group consisting of lactate dehydrogenase (LDH), guanine deaminase (GDA), collapsin response mediator protein 1 (CRMP1), stress-induced phosphoprotein 1 (STIP1), alpha subunit of the barbed-end actin binding protein Cap Z (CAPZA2), Y Box Binding Protein 1 (YBX1), eukaryotic translation and elongation factor 1A1 (EEF1A1), microtubule-associated protein Tau (MAPT), dihydropyrimidinase-like protein 2 (DPYSL2), dynamin 1-like protein (DNM1L), radixin (RDX), moesin (MSN), and ezrin (EZR).
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: February 26, 2013
    Assignee: The Regents of the University of California
    Inventors: Judy Van de Water, Daniel Braunschweig
  • Patent number: 8163475
    Abstract: The invention features methods diagnostic of a psychotic disorder such as bipolar disorder or schizophrenia. The methods include obtaining a cell sample from a subject, subjecting a cell from the sample to stress (e.g., nutrient stress), and measuring nucleic acid or polypeptide expression in the cell, where an alteration in expression is indicative of the subject having or being at increased risk of developing a psychotic disorder. The invention also features prognostic monitoring methods for subjects having a psychotic disorder, useful in determining the progression of a psychotic disorder in a subject or the effectiveness of a therapy.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: April 24, 2012
    Assignee: The McLean Hospital Corporation
    Inventor: Christine Konradi
  • Patent number: 8148093
    Abstract: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: April 3, 2012
    Assignee: diaDexus, Inc.
    Inventors: Iris Simon, Laura Corral, Charis Lawrenson, Nam Kim, Glenn Pilkington, Robert L. Wolfert
  • Patent number: 8143010
    Abstract: The present invention relates to novel prostate specific nucleic acid molecules and polypeptides and related methods for diagnosing or predicting susceptibility to a prostate neoplastic condition.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: March 27, 2012
    Assignee: Institute for Systems Biology
    Inventor: Biaoyang Lin
  • Patent number: 8138360
    Abstract: Benzofuran compounds which contain at least one detectable label selected from the group consisting of 131I, 123I, 124I, 125I, 76Br, 75Br, 18F, 19F, 11C, 13C, 14C and 3H are provided as amyloid imaging agents for detecting brain amyloid deposits as well as other amyloidogenic peptides associated with systemic or localized amyloidosis. Additionally, the compounds are useful for determining if patients, presenting with clinically confusing cases of dementia or presenting with mild cognitive impairment, have Alzheimer's disease. The compounds are additionally useful as surrogate markers for monitoring the efficacy of anti-amyloidosis therapies.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: March 20, 2012
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: William E. Klunk, Chester A. Mathis, Jr.
  • Patent number: 8039226
    Abstract: The present invention dedicates to detect nephritis in early stage of either primary or secondary nephritis using an anti NC1 monoclonal antibody. The present invention dedicates to provide useful information for diagnosis of renal function to detect NC1 by immunofluorescent stain method in renal biopsy section obtained at early stage where immunoglobulins do not deposit yet in renal GBM etc, or by antigen-antibody reaction in urine or serum specimens. Furthermore, the present invention comprises to utilize for therapeutic use.
    Type: Grant
    Filed: February 15, 2005
    Date of Patent: October 18, 2011
    Inventors: Tsukao Yokoyama, Toshiyuki Imasawa
  • Patent number: 8003406
    Abstract: The invention provides a method of determining a susceptibility of a subject for development of ADHD. The method comprises obtaining a sample from the subject, analyzing the sample for an ADHD susceptibility haplotype of LPHN3 receptor which is associated with at least one genetic marker selected from the group consisting of rs7678046, rs1901223, rs6813183, and rs1355368, and determining if the subject has a susceptibility to develop ADHD, whereby the presence of the haplotype having one or more of the genetic markers is indicative of a susceptibility to develop ADHD. The invention also provides methods of treating ADHD.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: August 23, 2011
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Maximilian Muenke, Mauricio Arcos-Burgos, F. Xavier Castellanos
  • Patent number: 7981692
    Abstract: Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gene or genes are immunologically quantitated in biological samples. Results indicating that a targeted wild-type protein is not present in an assayed sample, or that approximately 50% of the normal amount of such a wild-type protein is present in an assayed sample are considered to be positive for a mutation in one or both alleles of a subject gene, and correlated with the disease or the disease susceptibility trait associated with that mutation or mutations. Normal cells, particularly normal peripheral blood lymphocytes, are preferred biological samples.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: July 19, 2011
    Assignee: CA*TX Inc.
    Inventor: Bruce M. Boman
  • Publication number: 20110076696
    Abstract: The present invention provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during the development of new therapeutics and other agents.
    Type: Application
    Filed: August 20, 2010
    Publication date: March 31, 2011
    Applicant: JANSSEN PHARMACEUTICA, N.V.
    Inventors: GODELIEVE IRMA CHRISTINE MARIA HEYLEN, CORNELUS GERARDUS MARIA JANSSEN, JURZAK MIREK, HENRICUS PETRUS MARTINUS MARIA VAN ASSOUW
  • Patent number: 7892857
    Abstract: The invention relates to an assay method and a fluid microsystem for carrying out said assay method, in particular, for carrying out miniaturized affinity tests in a micro-array format. According to said invention, a liquid phase comprising at least one type of detectable high-molecular weight soluble substance, for example a labeled reaction partner or product of an affinity reaction is displaced by the hydraulic effect of a high-molecular weight osmotic agent on an ultrafiltration membrane towards a miniaturized measuring chamber defined thereby. The fraction of the detectable high-molecular weight substance(s) is concentrated in the measuring chamber, while the dissolved low-molecular weight components are removed with the solvent through the membrane pores, thereby making it possible to attain a high detection sensitivity.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: February 22, 2011
    Inventors: Rudolf Ehwald, Helge Adleff, Frank Bier, Nenad Gajovic-Eichelmann, Max Ehwald
  • Patent number: 7867717
    Abstract: Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gene or genes are immunologically quantitated in biological samples. Results indicating that a targeted wild-type protein is not present in an assayed sample, or that approximately 50% of the normal amount of such a wild-type protein is present in an assayed sample are considered to be positive for a mutation in one or both alleles of a subject gene, and correlated with the disease or the disease susceptibility trait associated with that mutation or mutations. Normal cells, particularly normal peripheral blood lymphocytes, are preferred biological samples.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: January 11, 2011
    Inventor: Bruce M. Boman
  • Patent number: 7820453
    Abstract: The present invention provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during the development of new therapeutics and other agents.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: October 26, 2010
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Godelieve Irma Christine Maria Heylen, Cornelus Gerardus Maria Janssen, Mirek Jurzak, Henricus Petrus Martinus Maria Van Assouw
  • Patent number: 7811828
    Abstract: Described is a method for identifying and quantifying of tumour-associated peptides, wherein first at least two different sources for obtaining the peptide are provided (tumourous and healthy tissue), and, separately of one another, the peptides from the different sources are chemically modified in an identical manner by using at least two different stable isotopes of the same element. Subsequently, the peptides are isolated by a chromatographic method, and the amino acid sequences of the peptides are determined, wherein the determination of the relative amount ratios of peptides having the identical sequence from different samples one to the other occurs by using a stable isotope in the chemical modification. Furthermore, the invention relates to a tumour-associated peptide having an amino acid sequence that is selected from the group consisting of SEQ-ID No.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: October 12, 2010
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Claudia Lemmel, Hans-Georg Rammensee
  • Patent number: 7807362
    Abstract: This invention features methods and compositions useful for the treatment and diagnosis of attentional disorders including attention deficit hyperactivity disorder (ADHD). Also disclosed are methods for identifying compounds useful for such therapy.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: October 5, 2010
    Assignee: The McLean Hospital Corporation
    Inventors: Kwang-Soo Kim, Chun-Hyung Kim
  • Patent number: 7776538
    Abstract: Disclosed is useful means for the therapy or diagnosis of a mental disorder. A method for screening for a compound which is effective for a mental disorder, comprising the steps of (1) providing a cell capable of expressing a gene (target gene) selected from the group consisting of a gene having the nucleotide sequence depicted in SEQ ID NO:1, a gene having the nucleotide sequence depicted in SEQ ID NO:2, a gene having the nucleotide sequence depicted in SEQ ID NO:3 and genes homologous to these genes; (2) exposing the cell to a compound to be tested; (3) determining the amount of a product of the target gene expressed in the cell after the exposure to the compound; and (4) determining the change in amount of the product of the target gene under the influence of exposure to the compound.
    Type: Grant
    Filed: February 24, 2006
    Date of Patent: August 17, 2010
    Assignee: National University Corporation Nagoya University
    Inventors: Atsumi Nitta, Minae Niwa, Toshitaka Nabeshima
  • Patent number: 7776553
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: August 17, 2010
    Assignee: Presidents and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 7749695
    Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: July 6, 2010
    Inventors: Alexander Abbas, Sarah Bodary, Hilary Clark, P Mickey Williams, Thomas D Wu
  • Patent number: 7745127
    Abstract: The present invention describes methods of molecular diagnosis of a concrete form of a-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB.
    Type: Grant
    Filed: July 18, 2005
    Date of Patent: June 29, 2010
    Assignee: Oryzon Genomics, S.A.
    Inventors: Tamara Maes, Carlos Buesa Arjol, Marta Barrachina Castillo, Isidro Ferrer Abizanda
  • Patent number: 7723057
    Abstract: A screening assay for selecting macromolecules that interfere with the binding of a sulfated GAG to beta amyloid, the assay comprising affixing a sulfated GAG to a substrate, co-incubating the macromolecule and a known amount of beta amyloid with the sulfated GAG, determining the amount of beta amyloid bound to the sulfated GAG affixed to the substrate; wherein the macromolecule will be one which interferes with the binding of the sulfated GAG to beta amyloid.
    Type: Grant
    Filed: March 30, 1999
    Date of Patent: May 25, 2010
    Assignee: Proteotech, Inc.
    Inventor: Alan D. Snow
  • Patent number: 7709270
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: May 4, 2010
    Assignee: Vegenics Ltd.
    Inventors: Kari Alitalo, Vladimir Joukov
  • Patent number: 7622259
    Abstract: The present invention relates to a method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib(?) (GPIb(?) and ristocetin, or a functionally equivalent substance. Additionally, the invention relates to the use of the aforementioned soluble form or portion of glycoprotein Ib(?), of ristocetin or a functional equivalent substance, of specifically reacting anti-GPIB(?) antibody(ies) and/or of specific binding partners, like specifically reacting anti-vWF antibody(ies) for carrying out the method of the invention. Furthermore, the present invention relates to kits for carrying out the method of the invention.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: November 24, 2009
    Assignee: K.U. Leuven Research & Development
    Inventors: Nancy Cauwenberghs, Karen Vanhoorelbeke, Hans Deckmyn
  • Patent number: 7544792
    Abstract: Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed.
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: June 9, 2009
    Assignee: Gen-Probe Incorporated
    Inventors: James D. Carlson, Steven T. Brentano
  • Patent number: 7517908
    Abstract: A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enahancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.
    Type: Grant
    Filed: May 20, 2005
    Date of Patent: April 14, 2009
    Assignee: Duke University
    Inventors: Ranga R. Krishnan, Marc G. Caron, Xiaodong Zhang, Martin Beaulieu, Raul R. Gainetdinova, Tatiana D. Sotnikova
  • Patent number: 7455964
    Abstract: The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: November 25, 2008
    Assignees: The Hospital for Sick Children, The Regents of the University of California
    Inventors: Joe W. Gray, Colin Conrad Collins, Soo-in Hwang, Tony Godfrey, David Kowbel, Johanna Rommens
  • Patent number: 7449291
    Abstract: In one aspect, the invention provides methods of identifying genetic mutations that are associated with peripheral neurological disease. The methods comprise identifying a difference between a nucleic acid sequence of a small integral protein of the lysosome/late endosome (“SIMPLE”) gene from a mammalian subject exhibiting peripheral neuropathy and a nucleic acid sequence of a SIMPLE gene from a subject which is not exhibiting peripheral neuropathy, wherein the difference is a genetic mutation associated with peripheral neurological disease. In another aspect, isolated nucleic acid molecules encoding SIMPLE missense mutations are provided. In another aspect, a method of screening a subject to determine if the subject has a genetic predisposition to develop Charcot-Marie-Tooth type 1C neuropathy is provided. In another aspect, the invention provides kits for determining susceptibility or presence of Charcot-Marie-Tooth type 1C neuropathy in a mammalian subject.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: November 11, 2008
    Assignee: University of Washington
    Inventors: Phillip F. Chance, Valerie A. Street, Jeff D. Goldy, Thomas D. Bird
  • Patent number: 7384748
    Abstract: The present invention relates to the NTE proteins and nucleic acids encoding the NTE proteins. The present invention further provides assays for the detection of NTE polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of NTE proteins.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: June 10, 2008
    Assignee: The Regents of the University of Michigan
    Inventors: John K. Fink, Shirley Rainer
  • Patent number: 7368253
    Abstract: Markers for TSE that are present prior to formation of detectable pathological prion protein are useful to detect this infection prior to clinical signs. Additional markers are useful to detect the stage of TSE infection and distinguish it from other conditions which have similar clinical symptoms. Determinations on isolated cell preparations are particularly useful, especially those derived from peripheral (non-brain) sources.
    Type: Grant
    Filed: March 4, 2005
    Date of Patent: May 6, 2008
    Inventor: Laura Manuelidis
  • Patent number: 7357915
    Abstract: A method of imaging apoptosis in vivo, using radiolabeled annexin, is described.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: April 15, 2008
    Assignees: The Board of Trustees of the Leland Stanford Junior University, University of Washington
    Inventors: Francis G. Blankenberg, H. W. Strauss, Jonathan F. Tait, Peter D. Katsikis
  • Patent number: 7358063
    Abstract: A method of detecting PS2V characterized by comprising reacting PS2V in a sample with a primary antibody which is bonded to a solid phase and specifically recognizes PA2V, then reacting with a secondary antibody recognizing PS2 or PS2V by any of the following procedures: (a) reacting with a secondary antibody having been enzyme-labeled and recognizing PS2 or PS2V; (b) reacting with a secondary antibody having been biotinylated and recognizing PS2 or PS2V and then reacting with an avidinylated or streptoavidinylated enzyme; (c) reacting with a secondary antibody having been biotinylated and recognizing PS2 or PS2V and then reacting with a biotinylated enzyme and avidin or streptoavidin; and (d) reacting with a secondary antibody recognizing PS2 or PS2V and then reacting with an antibody having been enzyme-labeled and recognizing the secondary antibody; then adding the substrate of the above enzyme and detecting the product formed by the enzyme reaction.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: April 15, 2008
    Assignees: Sysmex Corporation
    Inventors: Masaya Tohyama, Yuichi Yasuda, Yasushi Hasui, Hideki Ishihara, Koichi Yamagata
  • Publication number: 20080026995
    Abstract: The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human use and is coupled at its free end to a phospholipids, e.g., phosphatidylethanolamine or any other chemically suitable phospholipid.
    Type: Application
    Filed: October 18, 2006
    Publication date: January 31, 2008
    Applicant: AC IMMUNE SA
    Inventors: Pierre-Francois Tosi, Claudie Madoulet, Yves-Claude Nicolau, David T. Hickman
  • Patent number: 7303895
    Abstract: The invention concerns the identification of a novel family of CTL (Choline Transporter Like) genes, in particular hCTL1 and hCTL2, involved in the metabolism and/or transport of choline in cells such as the intestinal tract cells, nervous cells, in particular motoneurons, sensitive neurons, neurons of the nucleus dorsalis of the spinal cord and oligodendrocytes. The invention opens up new prospects in particular for the treatment of familial dysautonomia, and Tangier disease. More generally, the identification of CTL genes enables to develop new strategies for treating diseases of the nervous system, in particular neurodegenerative demyelenating diseases, particularly Alzheimer disease, Parkinson disease and Huntington disease.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: December 4, 2007
    Assignee: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Seana O'Regan, François Meunier, Elisabeth Traiffort, Martial Ruat
  • Patent number: 7303885
    Abstract: The present invention relates to methods for screening molecules and methods to detect protein-protein interactions and means used therein. More specifically, the present invention relates to methods for screening candidate drugs for treating or detecting MIF (macrophage migration inhibitor factor) related diseases. In certain aspects, the present invention involves detecting MIF/Jab1 (c-Jun activation domain binding protein) interactions as a basis for modulating cellular regulatory pathways and for identifying candidate drugs for MIF-related diseases. The invention also provides methods for the identification of molecules which dissociate or prevent interaction or binding between MIF and Jab1.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: December 4, 2007
    Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.
    Inventors: Herwig Brunner, Jürgen Bernhagen, Robert Kleemann, Ralf Mischke, Afroditi Kapurniotu
  • Patent number: 7294477
    Abstract: The present invention is related to novel nucleoli sequences encoding a louse allergen and a methods for diagnosing, treating and preventing lice infestation and associated allergic disease with the nucleoli sequences and protein allergen of the invention. The present invention also relates to kits for diagnostic assays.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: November 13, 2007
    Assignee: Ovita Limited
    Inventors: Alexander Terrance Pfeffer, Charles Bix Shoemaker
  • Patent number: 7285648
    Abstract: DNA encoding IL-1 delta polypeptides and methods for using the DNA and encoded polypeptides are disclosed.
    Type: Grant
    Filed: July 10, 2000
    Date of Patent: October 23, 2007
    Assignee: Immunex Corporation
    Inventor: John E. Sims
  • Patent number: 7270960
    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: September 18, 2007
    Assignee: Pacific Northwest Research Institute
    Inventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
  • Patent number: 7250265
    Abstract: Disclosed is a method of screening a substance for angiotensinogen receptor-modulatory activity. The method includes the steps of contacting placental-derived cells with labeled angiotensinogen and a candidate substance; and then determining whether the candidate substance inhibits the binding of angiotensinogen to the placental-derived cells relative to a control wherein the placental-derived cells are contacted with angiotensinogen in the absence of the candidate substance.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: July 31, 2007
    Assignee: Marshfield Clinic
    Inventor: Duane A. Tewksbury
  • Patent number: 7223846
    Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn II. Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: May 29, 2007
    Assignee: Research Development Foundation
    Inventors: Wylie Walker Vale, Jr., Teresa M Reyes, Paul E Sawchenko, Jean E F Rivier, Kathy A Lewis, John B Hogenesch, Joan M Vaughan, Marilyn H Perrin
  • Patent number: 7148016
    Abstract: Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gene or genes are immunologically quantitated in biological samples. Results indicating that a targeted wild-type protein is not present in an assayed sample, or that approximately 50% of the normal amount of such a wild-type protein is present in an assayed sample are considered to be positive for a mutation in one or both alleles of a subject gene, and correlated with the disease or the disease susceptibility trait associated with that mutation or mutations. Normal cells, particularly normal peripheral blood lymphocytes, are preferred biological samples.
    Type: Grant
    Filed: January 11, 2000
    Date of Patent: December 12, 2006
    Inventor: Bruce M. Boman
  • Patent number: 7135298
    Abstract: The present invention provides an assay for the identification of agents which can modulate TOR-mediated phosphorylation of substrate proteins. The assays of the invention utilize substrate proteins whose amino acid sequence contains the Ser/Thr motif recognized by TOR. Naturally occurring TOR which may be used in the methods of the invention include TOR isolated from a variety of species, particularly mammalian tissues.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: November 14, 2006
    Assignee: The Burnham Institute for Medical Research
    Inventor: Robert T. Abraham
  • Patent number: 7094535
    Abstract: Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: August 22, 2006
    Assignee: Gilead Sciences, Inc.
    Inventors: Judy Ruckman, Larry Gold, Andrew Stephens, Nebojsa Janjic
  • Patent number: RE43497
    Abstract: The present invention relates to methods for screening molecules and methods to detect protein-protein interactions and means used therein. More specifically, the present invention relates to methods for screening candidate drugs for treating or detecting MIF (macrophage migration inhibitor factor) related diseases. In certain aspects, the present invention involves detecting MIF/Jab1 (c-Jun activation domain binding protein) interactions as a basis for modulating cellular regulatory pathways and for identifying candidate drugs for MIF-related diseases. The invention also provides methods for the identification of molecules which dissociate or prevent interaction or binding between MIF and Jab1.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: June 26, 2012
    Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.
    Inventors: Herwig Brunner, Jürgen Bernhagen, Robert Kleemann, Ralf Mischke, Afroditi Kapurniotu